Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Machine learning accurately classified clear cell renal cell carcinoma (RCC) into molecular subtypes using transcriptomic data. Immune checkpoint inhibitor therapy showed benefits across all subtypes in the JAVELIN Renal 101 trial.
Area Of Science
- Oncology
- Bioinformatics
- Genomics
Background
- Clear cell renal cell carcinoma (ccRCC) is a complex disease with diverse molecular profiles.
- Transcriptomic data offers a powerful tool for dissecting tumor heterogeneity.
- Machine learning (ML) algorithms can identify complex patterns in high-dimensional biological data.
Discussion
- This study demonstrates the utility of ML in classifying ccRCC into distinct molecular subtypes based on transcriptomic signatures.
- The findings suggest that these molecular subtypes may have implications for treatment response.
- The JAVELIN Renal 101 trial data provides a robust clinical validation dataset.
Key Insights
- A novel ML approach accurately categorizes ccRCC into molecular subtypes using transcriptomic data.
- Immune checkpoint inhibitor (ICI) therapy demonstrated a consistent benefit across all identified molecular subtypes.
- This molecular subtyping may refine patient stratification for ICI treatment in ccRCC.
Outlook
- Further validation of this ML-based subtyping in larger, independent cohorts is warranted.
- Investigating the specific biological mechanisms underlying ICI response within each subtype could reveal novel therapeutic targets.
- This approach holds promise for personalized medicine strategies in renal cell carcinoma treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...